Related Experiment Videos

Adverse drug reactions among children over a 10-year period

Jennifer Le1, Thuy Nguyen, Anandi V Law

  • 1Department of Pharmacy Practice, College of Pharmacy, Western University of Health Sciences, 309 E Second St, Pomona, California 91766-1854, USA. jle@westernu.edu

Pediatrics
|August 3, 2006
PubMed

Insights

Pediatric adverse drug reactions (ADRs) occur in 1.6% of hospitalizations, often mild. Reporting and follow-up processes require improvement for better patient safety and understanding of drug effects in children.

Area of Science:

  • Pediatric pharmacology
  • Patient safety
  • Drug surveillance

Background:

  • Adverse drug reactions (ADRs) are a significant concern in pediatric healthcare.
  • Understanding the incidence, types, and reporting of ADRs in children is crucial for improving patient outcomes.
  • Current reporting and follow-up mechanisms may be suboptimal.

Purpose of the Study:

  • To determine the incidence and common types of ADRs in hospitalized children.
  • To assess the frequency of ADR reporting by healthcare providers.
  • To evaluate the follow-up processes for ADRs in a pediatric setting.

Main Methods:

  • Retrospective cohort study design.
  • Inclusion of pediatric patients with ADRs from January 1995 to December 2004.
  • Data collected from a community-based, tertiary care children's teaching hospital.

Main Results:

  • 1087 ADRs reported, with an overall incidence of 1.6%.
  • Most ADRs were low severity (89%); high-severity ADRs were associated with hospital admission, surgery, anticonvulsants, and antineoplastic agents.
  • Pharmacists reported 89% of ADRs; physician reporting was <1%. Documentation in charts and allergy profiles was low (29% and 10%, respectively).

Conclusions:

  • There is a need to enhance the detection and reporting of ADRs by all healthcare professionals, including physicians.
  • Improved reporting systems are essential for a comprehensive understanding of ADRs in pediatric populations.
  • Enhancing follow-up and documentation processes can improve patient safety and medication management.
Abstract

Related Concept Videos

Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...